BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22332446)

  • 1. High yield of oocytes without an increase in circulating estradiol levels in breast cancer patients treated with follicle-stimulating hormone and aromatase inhibitor in standard gonadotropin-releasing hormone analogue protocols.
    Ben-Haroush A; Farhi J; Ben-Aharon I; Sapir O; Pinkas H; Fisch B
    Isr Med Assoc J; 2011 Dec; 13(12):753-6. PubMed ID: 22332446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI.
    Mohsen IA; El Din RE
    Gynecol Endocrinol; 2013 Feb; 29(2):105-8. PubMed ID: 23134528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report.
    Goswami SK; Das T; Chattopadhyay R; Sawhney V; Kumar J; Chaudhury K; Chakravarty BN; Kabir SN
    Hum Reprod; 2004 Sep; 19(9):2031-5. PubMed ID: 15217999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization].
    Ye H; Huang G; Pei L
    Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
    Fatum M; McVeigh E; Child T
    Hum Fertil (Camb); 2013 Dec; 16(4):235-40. PubMed ID: 23863119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
    Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
    Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.
    Azim AA; Costantini-Ferrando M; Lostritto K; Oktay K
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2197-200. PubMed ID: 17356042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy.
    Oktay K; Hourvitz A; Sahin G; Oktem O; Safro B; Cil A; Bang H
    J Clin Endocrinol Metab; 2006 Oct; 91(10):3885-90. PubMed ID: 16882752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparision of effect of microdose GnRH-a flare-up, GnRH antagonist/aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients.
    Ozcan Cenksoy P; Ficicioglu C; Kizilkale O; Suhha Bostanci M; Bakacak M; Yesiladali M; Kaspar C
    Gynecol Endocrinol; 2014 Jul; 30(7):485-9. PubMed ID: 24592985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years.
    D'Amato G; Caroppo E; Pasquadibisceglie A; Carone D; Vitti A; Vizziello GM
    Fertil Steril; 2004 Jun; 81(6):1572-7. PubMed ID: 15193479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone in controlled ovarian hyperstimulation: a prospective, randomized, blinded clinical trial.
    Barroso G; Menocal G; Felix H; Rojas-Ruiz JC; Arslan M; Oehninger S
    Fertil Steril; 2006 Nov; 86(5):1428-31. PubMed ID: 16978619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study.
    Olgan S; Humaidan P
    Reprod Biol; 2017 Mar; 17(1):105-110. PubMed ID: 28173995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.